Compare Grab Holdings Ltd. (GRAB) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Heron Therapeutics Inc — how do they compare? Grab Holdings Ltd. trades at $3.13 (market cap $12.60B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Grab Holdings Ltd. is far larger — about 170.2× Heron Therapeutics Inc's market cap, and Grab Holdings Ltd. is more actively traded (87,608,440 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Heron Therapeutics Inc for 35 Days on average.
| GRAB | HRTX | |
|---|---|---|
Market Cap | $12.60B | $74.04M |
Volume | 87,608,440 | 3,668,095 |
Sector | Technology | Health |
52-Week High | $6.17 | $1.49 |
52-Week Low | $2.80 | $0.27 |
Typical Hold Time | 94 Days | 35 Days |
Enterprise Value | $8.33B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.11, up 1.3% today, with a bearish technical signal but strong fundamentals including a 22% YoY revenue growth in Q2 2026 and a net income margin of 16.03%. Recent news highlights a $30 million CEO share purchase and the acquisition of a 60% stake in Atome Financial for $1.49 billion, signaling confidence and expansion in financial services.
The outlook is positive with robust earnings beats and a 91.67% analyst buy rating, though risks include high capital expenditure, regional regulatory challenges, and volatile cash flows. The stock's current valuation at a P/E of 28 reflects growth expectations amid competitive pressures.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
